5-Amino-1MQ for Fat Loss
Research, mechanism, dosing, and effectiveness of 5-Amino-1MQ for fat loss.
Quick Answer
5-Amino-1MQ inhibits NNMT enzyme linked to fat accumulation.
Evidence Level
Animal Studies
Typical Dose
50-150 mg oral daily
Results Timeline
Fat loss effects over 4-8 weeks
FDA Status
Research Only
How 5-Amino-1MQ Works for Fat Loss
NNMT inhibition reduces fat cell proliferation and may boost metabolism.
About Fat Loss
Reduction of body fat while preserving lean muscle mass.
Research Evidence
Mouse studies showed over 30% decrease in adipocyte size and 40% decrease in adipocyte volume. Treated mice had 30% lower total cholesterol. No significant impact on food intake or adverse effects observed. Human clinical data remains limited.
Dosing for Fat Loss
Recommended Dose
50-150 mg oral daily
Frequency
Once daily, morning
Administration
Subcutaneous injection or oral
Duration
4-6 weeks (cycling recommended)
Note: Small molecule NNMT inhibitor. Cycle 4-6 weeks on, 2-4 weeks off. Weight-based: <150 lbs: 50-75mg, 150-200 lbs: 75mg, >200 lbs: 75-100mg.
What to Expect
Initial adjustment period. Some users may notice subtle changes.
Early benefits often become noticeable. Continue consistent use.
Most users report meaningful improvements by this point.
Full effects typically realized. Reassess and adjust as needed.
Possible Side Effects
Not everyone experiences these. Individual responses vary.
- •Mild headache (initial dosing)
- •Nausea
- •Increased alertness/jitteriness
- •Rare: insomnia
- •Rare: elevated blood pressure
Frequently Asked Questions
Does 5-Amino-1MQ help with fat loss?
5-Amino-1MQ inhibits NNMT enzyme linked to fat accumulation.
How does 5-Amino-1MQ work for fat loss?
NNMT inhibition reduces fat cell proliferation and may boost metabolism....
What dose of 5-Amino-1MQ should I use for fat loss?
50-150 mg oral daily
How long until I see results?
Fat loss effects over 4-8 weeks
Other Peptides for Fat Loss
These peptides are also researched for fat loss.
Semaglutide
FDAA GLP-1 receptor agonist with multiple FDA approvals including weight loss, T2D, CV risk reduction, and kidney protection. Wegovy pill approved Dec 2025 as first oral GLP-1 for weight loss.
Tirzepatide
FDAA dual GIP/GLP-1 receptor agonist representing the next generation of incretin-based therapies. Shows superior weight loss compared to semaglutide in head-to-head trials. First medication approved for obstructive sleep apnea.
Retatrutide
Clinical TrialsA triple agonist targeting GLP-1, GIP, and glucagon receptors. Phase 3 trials show up to 28.7% weight loss (71 lbs average), the highest of any obesity drug. Expected FDA approval late 2026 to early 2027.
Orforglipron
Clinical TrialsAn oral non-peptide GLP-1 receptor agonist. NDA submitted to FDA with Priority Review. Expected approval by mid-2026.
Educational Information Only
This information about 5-Amino-1MQ for fat loss is for educational purposes only. Always consult with qualified healthcare providers before using any peptide. Individual results may vary.